Patrizia Cavazzoni, MD, will return to Pfizer as the Chief Medical Officer and Executive Vice President. She will report directly to Chris Boshoff, MD, PhD, Chief Scientific Officer and President of Pfizer Research & Development. Dr. Cavazzoni will succeed Aida Habtezion, MD, MSc, FRCPC, AGAF.

Dr. Cavazzoni has over 25 years of experience in clinical development, pharmacovigilance, regulatory affairs, and drug safety. Most recently, she served as Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), where she helped advance regulatory science and ensured the availability of safe and effective medicines. 

Before leadership at the FDA, Dr. Cavazzoni spent nearly 2 decades in the pharmaceutical industry, holding senior executive roles at Pfizer, Eli Lilly, and Sanofi. She previously worked at Pfizer in various clinical development leadership positions.

Dr. Cavazzoni earned her medical degree from McGill University and completed her psychiatry residency and a fellowship in mood disorders at the University of Ottawa. She has authored numerous peer-reviewed scientific publications.